Petrelintide, a long-acting human amylin analogue, provides clinically meaningful weight loss in obese adults over 28 to 42 weeks of treatment.
Once-weekly subcutaneous administration achieves up to approximately 10.7% bodyweight reduction compared with 1.7% with placebo.
Gastrointestinal side effects are predominantly mild nausea during dose escalation, with low rates of vomiting, diarrhea, or constipation similar to placebo.
This phase 2 trial supports further development of petrelintide as a novel obesity treatment distinct from incretin-based therapies.
